Integrating Patient‐Centric Clinical Pharmacology and MID3 to Advance Biologic Development in Immune‐Mediated Inflammatory Diseases
{"Advances":[0],"in":[1,85,128],"biologics":[2],"and":[3,7,22,35,48,59,67,105,108,113,135],"model-informed":[4],"drug":[5],"discovery":[6],"development":[8,64],"(MID3)":[9],"are":[10,116],"transforming":[11],"the":[12,71,81,86,118],"treatment":[13,53],"of":[14,65,88,121],"immune-mediated":[15],"inflammatory":[16,129],"diseases":[17],"(IMIDs).":[18],"By":[19],"integrating":[20],"pharmacokinetics":[21],"pharmacodynamics,":[23],"MID3":[24,96,112],"enables":[25],"mechanism-based,":[26],"patient-centered":[27],"strategies":[28],"to":[29],"optimize":[30],"therapies,":[31,124],"strengthen":[32],"benefit-risk":[33],"assessment,":[34],"advance":[36],"precision":[37,114],"medicine.":[38,61],"Innovations":[39],"such":[40],"as":[41],"cytokine":[42],"inhibitors,":[43],"bispecific":[44],"antibodies,":[45],"antibody-drug":[46],"conjugates,":[47],"mRNA":[49],"therapies":[50],"have":[51],"expanded":[52],"options":[54],"across":[55],"dermatology,":[56],"rheumatology,":[57],"gastroenterology,":[58],"respiratory":[60],"The":[62],"rapid":[63],"JAK-":[66],"interleukin-targeted":[68],"agents":[69],"underscores":[70],"shift":[72],"toward":[73],"individualized,":[74],"mechanistically":[75],"driven":[76],"therapies.":[77],"At":[78],"ASCPT":[79],"2025,":[80],"session":[82],"\\"Transformative":[83],"Advancements":[84],"Treatment":[87],"IMIDs:":[89],"Integrating":[90],"Patient-Centric":[91],"Clinical":[92],"Pharmacology":[93],"with":[94,125],"Translational":[95],"for":[97],"Biologics\\"":[98],"brought":[99],"together":[100],"experts":[101],"from":[102],"academia,":[103],"industry,":[104],"regulatory":[106],"agencies":[107],"emphasized":[109],"how":[110],"translational":[111],"pharmacology":[115],"accelerating":[117],"next":[119],"generation":[120],"patient-tailored":[122],"biologic":[123],"case":[126],"studies":[127],"bowel":[130],"disease,":[131],"systemic":[132],"lupus":[133],"erythematosus,":[134],"rheumatology.":[136]}
Authors
- Brian Cicali (ORCID: https://orcid.org/0000-0002-7932-8599)
- Sihem Ait‐Oudhia (ORCID: https://orcid.org/0000-0002-9794-8601)
- Dipak S. Pisal (ORCID: https://orcid.org/0009-0003-0551-3892)
- Li Zhang (ORCID: https://orcid.org/0009-0005-5846-2296)
Institutions
- University of Central Florida (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Center for Drug Evaluation and Research (US)
- Daiichi Sankyo (United States) (US)
Publication Details
- Journal
- Clinical Pharmacology & Therapeutics
- Published
- 2026-09-03
- DOI
- https://doi.org/10.1002/cpt.70471
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00